<DOC>
	<DOCNO>NCT00399945</DOCNO>
	<brief_summary>This study assess aerosol delivery characteristic ( measure vivo lung deposition , nebulization time , serum tobramycin concentration , pharmacokinetic parameter ) safety tobramycin inhalation solution administer inhalation PARI eFlow rapid electronic nebulizer ( compressor ) vs. PARI LC PLUS Jet Nebulizer ( compressor ) healthy subject subject cystic fibrosis .</brief_summary>
	<brief_title>Tobramycin Inhalation Solution Administered eFlow Rapid Nebulizer : Scintigraphy Study</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>All subject : Provide write informed consent prior performance studyrelated procedure . Be 18 65 year age screening . Weigh within Â± 25 % ideal use body mass index method . Able comply protocol requirement . Healthy Subjects : Be healthy male nonpregnant , nonbreastfeeding healthy female . Have force expiratory volume one second ( FEV1 ) least 80 % predict great base age , sex , height , race base European Community Steel Coal ( ECSC ) equation Subjects Cystic Fibrosis : Be chronically colonize Pseudomonas aeruginosa . Have diagnosis CF document sweat chloride 60 mEq/L great quantitative pilocarpine iontophoresis test ( QPIT ) and/or genotype two identifiable mutation consistent CF , accompany one clinical feature consistent CF . Have FEV1 25 % predict value , calculate use ECSC equation base age , sex , height , race . Able tolerate 1week washout interval inhale tobramycin aminoglycoside treatment . Be clinically stable opinion refer investigator CF unit . All subject : Participation clinical research study within previous 1 month . History alcohol drug abuse . Positive result drug abuse . Regular alcohol consumption male females 21 unit 14 unit per week , respectively Known hypersensitivity salbutamol . Current smoker smoke within last 12 month . Breath carbon monoxide read great 10 ppm either prestudy medical examination study day prior dose . Females childbearing potential , pregnant plan become pregnant course study , breast feeding , sexually active either use reliable form contraception surgically sterile . Clinically significant abnormal biochemistry , hematology , urinalysis . Positive hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) result . Treatment investigational drug within 1 month screening . Treatment loop diuretic within 7 day study drug administration . Serum creatinine blood urea upper limit normal sex age , abnormal urine analysis define 2+ great proteinuria . Known local systemic hypersensitivity aminoglycosides . Healthy Subjects : Screening FEV1 le 80 % predict value sex , age , height , race use ECSC equation History chronic respiratory disorder , include asthma . Treatment tobramycin aminoglycosides within 1 week prior study . History adverse reaction allergy tobramycin aminoglycosides . History infantile bronchiolitis history presence asthma wheezy respiration . Upper respiratory tract infection ( exclude otitis medium ) within 14 day first study day low respiratory tract infection within last 3 month . Treatment medication may affect respiratory tract within 1 week first study day throughout study ( oral contraceptive , Hormone Replacement Therapy [ HRT ] , paracetamol permit ) ; Failure satisfy Principal Investigator regard fitness participate reason . Donation blood within previous 3 month . Treatment diuretic history renal failure . Radiation exposure clinical trial . No subject whose occupational exposure monitor eligible participate study . Subjects Cystic Fibrosis : Screening FEV1 le 25 % predict value sex , age , height , race use ECSC equation Treatment inhale intravenous aminoglycosides within 7 day study drug administration . Current treatment inhale tobramycin deliver PARI LC PLUS jet nebulizer washout period least 1 week enter study . Hemoptysis 60 mL time within 30 day study drug administration . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Cystic fibrosis , tobramycin , PARI eFlow , PARI LC Plus , nebulizer , pharmacoscintigraphy</keyword>
</DOC>